Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib for Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial
JAMA Oncol 2022 Sep 01;[EPub Ahead of Print], NM Tannir, N Agarwal, C Porta, NJ Lawrence, R Motzer, B McGregor, RJ Lee, RK Jain, N Davis, LJ Appleman, O Goodman, WM Stadler, S Gandhi, DM Geynisman, R Iacovelli, B Mellado, JM Sepúlveda Sánchez, R Figlin, T Powles, L Akella, K Orford, B EscudierFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.